This Literature case, one of 26 cases in a published article, reported by a health care professional, concerns an 
adult patient whose age was between 34-80 years (exact age, gender, and ethnicity were not provided), who was 
involved in a study. 
Medical history included non-small cell lung cancer (NSCLC) stage 1118 (malignant pleural effusion) or stage IV. 
The patient had not received prior chemotherapy, immunotherapy, biologic therapy, or antiangiogenic drugs. 
Concomitant medications included cyanocobalamin 1000 mg every nine weeks starting one week before the first 
cycle of pemetrexed. Folic acid 1 mg was also administered orally every day beginning one week before the first 
cycle of pemetrexed. 
The patient received pemetrexed (unknown manufacturer) 500 mg/m2 as a 10 minute intravenous (IV) infusion on 
day one immediately followed by carboplatin as a 30 minute IV infusion on day one, and then bevacEzumab 15 
mg/kg as a 30-90 minute IV infusion on day one for treatment of advanced nonsquamous NSCLC sometime 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 561 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
between Sep2005-Dec2009. On an unspecified date during cycles 1-6, the patient experienced Grade 3 dyspnea. 
Treatment measures, event outcome, and pemetrexed status were not provided. 
The author related the event to pemetrexed therapy. 
This case is associated with US201211002516 
Literature Citation: Stevenson James P, Langer Corey J, Somer Robert A, Evans Tracey L, Rajagopalan Kumar, 
Krieger Kimberly. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and 
carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer. 2012; 118 5580-5587.